Welcome to our dedicated page for PRECIGEN SEC filings (Ticker: PGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Precigen, Inc. filings document the company’s biopharmaceutical operations, commercial product disclosures, governance matters, and capital structure. Form 8-K reports cover financial results, PAPZIMEOS business updates, investor presentations, commercial supply arrangements, and financing agreements tied to the company’s transition into commercial-stage operations.
Precigen’s proxy materials describe board elections, auditor ratification, executive compensation votes, and equity incentive plan matters. Other filings disclose its Nasdaq-listed common stock, preferred-stock conversion activity, senior secured debt arrangements, material agreements, risk factors, and corporate governance controls relevant to a public precision-medicine company.
Precigen CFO Harry Thomasian Jr. received a significant equity award in the form of 175,000 Restricted Stock Units (RSUs) on June 26, 2025. The RSUs represent the right to receive an equivalent number of Precigen common stock shares.
The vesting schedule for these RSUs is structured as follows:
- 50% vesting on May 23, 2026 (initial cliff vesting)
- Remaining 50% vesting in equal monthly installments over the subsequent three years
This Form 4 filing, signed by Donald P. Lehr as attorney-in-fact, indicates a long-term retention strategy for the CFO position. The RSUs were granted at no cost ($0) to the executive, representing a significant equity incentive aligned with shareholder interests. The award demonstrates Precigen's commitment to executive compensation through equity-based incentives.